1. NCMP-23. FACIAL PALSY INDUCED BY CANCER IMMUNOTHERAPY: A SINGLE CENTER RETROSPECTIVE STUDY. (5th November 2018) Authors: Yuen, Carlen; Reid, Pankti; Soliven, Betty; Zhang, Zuoli; Luke, Jason; Rezania, Kourosh Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi198 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma. (9th November 2020) Authors: Milhem, Mohammed; Zakharia, Yousef; Davar, Diwakar; Buchbinder, Elizabeth; Medina, Theresa; Daud, Adil; Ribas, Antoni; Niu, Jiaxin; Gibney, Geoffrey; Margolin, Kim; Olszanski, Anthony; Mehmi, Inderjit; Sato, Takami; Shaheen, Montaser; Morris, Aaron; Mauro, David; Campbell, Katie; Kelley, Heather;... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 489 The impact of education on novel concepts in adjuvant melanoma: a closer look at high risk stage II disease. (9th November 2020) Authors: Parikh, Kinjal; Warren, Charlotte; Laar, Emily Van; Luke, Jason Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A525 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 489 The impact of education on novel concepts in adjuvant melanoma: a closer look at high risk stage II disease. (9th November 2020) Authors: Parikh, Kinjal; Warren, Charlotte; Laar, Emily Van; Luke, Jason Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A302 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms. (9th November 2020) Authors: Patel, Manish; Luke, Jason; Hamilton, Erika; Chmielowski, Bartosz; Blumenschein, George; Kindler, Hedy; Bahadur, Shakeela; Santa-Maria, Cesar; Koucheki, Janine; Sun, Jichao; Kaul, Sanjeev; Chen, Francine; Zhang, Xiaoyu; Muth, John; Kaminker, Patrick; Moore, Paul; Sumrow, Bradley; Ulahannan, Susanna Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A193 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 367 A phase 1/1b dose-escalation study of intravenously administered SB 11285 alone and in combination with atezolizumab in patients with advanced solid tumors. (9th November 2020) Authors: Luke, Jason; Janku, Filip; Olszanski, Anthony; Leach, Kevin; Iyer, Radhakrishnan; Abbas, Atif Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A224 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms. (9th November 2020) Authors: Patel, Manish; Luke, Jason; Hamilton, Erika; Chmielowski, Bartosz; Blumenschein, George; Kindler, Hedy; Bahadur, Shakeela; Santa-Maria, Cesar; Koucheki, Janine; Sun, Jichao; Kaul, Sanjeev; Chen, Francine; Zhang, Xiaoyu; Muth, John; Kaminker, Patrick; Moore, Paul; Sumrow, Bradley; Ulahannan, Susanna Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A340 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 435 A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma. (9th November 2020) Authors: Shaikh, Saba; Zang, Yan; Wang, Hong; Yang, Xi; Sander, Cindy; Rose, Amy; Davar, Diwakar; Luke, Jason; Zarour, Hassane; Kirkwood, John; Delgoffe, Greg; Najjar, Yana Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016) Authors: Ager, Casey; Reilley, Matthew; Nicholas, Courtney; Bartkowiak, Todd; Jaiswal, Ashvin; Curran, Michael; Albershardt, Tina C.; Bajaj, Anshika; Archer, Jacob F.; Reeves, Rebecca S.; Ngo, Lisa Y.; Berglund, Peter; ter Meulen, Jan; Denis, Caroline; Ghadially, Hormas; Arnoux, Thomas; Chanuc, Fabien; Fu... Journal: Journal for immunotherapy of cancer Issue: Volume 4(2016)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab. (15th April 2020) Authors: Milhem, Mohammed; Zakharia, Yousef; Davar, Diwakar; Buchbinder, Elizabeth; Medina, Theresa; Daud, Adil; Ribas, Antoni; Niu, Jiaxin; Gibney, Geoffrey; Margolin, Kim; Olszanski, Anthony; Mehmi, Interjit; Sato, Takami; Shaheen, Montaser; Morris, Aaron; Mauro, David; Campbell, Katie; Bao, Riyue; Wein... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 1 Page Start: A2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗